Editorial

Should we be combining local tumor therapies with immunotherapies as standard?

Christian Baues^†

Radio-Immune-Oncology (RIO) Consortium, University Hospital Cologne, Germany

Department of Radio-Oncology & CyberKnife Center University Hospital Cologne, Cologne, Germany

^†Shared first authorship

Search for more papers by this author

Max Schlaak^†

Radio-Immune-Oncology (RIO) Consortium, University Hospital Cologne, Germany

Department of Dermatology & Venereology, Skin Cancer Center, University Hospital Cologne, Cologne, Germany

^†Shared first authorship

Search for more papers by this author

Michael von Bergwelt-Baildon^‡

Radio-Immune-Oncology (RIO) Consortium, University Hospital Cologne, Germany

Department I for Internal Medicine, Center for Integrated Oncology (CIO) Köln Bonn, University Hospital Cologne, Cologne Germany

Cologne Interventional Immunology (CII), Department I for Internal Medicine, University Hospital Cologne, Germany

^‡Shared last authorship

Search for more papers by this author

Sebastian Theurich^‡

*Author for correspondence: Tel.: +49 221 478 3593; Fax: +49 221 478 1423575;

E-mail Address: sebastian.theurich@uk-koeln.de

Radio-Immune-Oncology (RIO) Consortium, University Hospital Cologne, Germany

Department I for Internal Medicine, Center for Integrated Oncology (CIO) Köln Bonn, University Hospital Cologne, Cologne Germany

Cancer & Immunometabolism Research Group, Department I for Internal Medicine, University Hospital Cologne, Germany

^‡Shared last authorship

Search for more papers by this author

Published Online:22 Aug 2017https://doi.org/10.2217/fon-2017-0150

View article

Keywords:

References

1 Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 5, 273–290 (1909).Google Scholar
2 Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).Crossref, Medline, CAS, Google Scholar
3 Topalian SL, Sznol M, Mcdermott DF et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32(10), 1020–1030 (2014).Crossref, Medline, CAS, Google Scholar
4 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006–2017 (2015).Crossref, Medline, Google Scholar
5 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and lpilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).Crossref, Medline, CAS, Google Scholar
6 Shahabi V, Postow MA, Tuck D, Wolchok JD. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am. J. Clin. Oncol. 38(1), 90–97 (2015).Crossref, Medline, CAS, Google Scholar
7 Heppt MV, Eigentler TK, Kahler KC et al. Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol. Immunother. 65(8), 951–959 (2016).Crossref, Medline, CAS, Google Scholar
8 Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int. J. Radiat. Oncol. Biol. Phys. 84(4), 879–880 (2012).Crossref, Medline, Google Scholar
9 Twyman-Saint Victor C, Rech AJ, Maity A et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520(7547), 373–377 (2015).Crossref, Medline, CAS, Google Scholar
10 Mole RH. Whole body irradiation; radiobiology or medicine? Br. J. Radiol. 26(305), 234–241 (1953).Crossref, Medline, CAS, Google Scholar
11 Theurich S, Rothschild SI, Hoffmann M et al. Local tumor treatment in combination with systemic lpilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Cancer Immunol. Res. 4(9), 744–754 (2016).Crossref, Medline, CAS, Google Scholar
12 Koller KM, Mackley HB, Liu J et al. Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. Cancer Biol. Ther. 18(1), 36–42 (2017).Crossref, Medline, CAS, Google Scholar
13 Hiniker SM, Reddy SA, Maecker HT et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int. J. Radiat. Oncol. Biol. Phys. 96(3), 578–588 (2016).Crossref, Medline, Google Scholar
14 Dummer R, Hoeller C, Gruter IP, Michielin O. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol. Immunother. doi:10.1007/s00262-017-1967-1 (2017) (Epub ahead of print).Crossref, Medline, Google Scholar
15 Fleeman N, Bagust A, Boland A et al. Talimogene laherparepvec for treating metastatic melanoma: an evidence review group perspective of a nice single technology appraisal. Pharmacoeconomics doi:10.1007/s40273-017-0504-6 (2017) (Epub ahead of print).Crossref, Medline, Google Scholar
16 Theurich S, Schlaak M, Steguweit H et al. Targeting tumor-infiltrating B cells in cutaneous T-cell lymphoma. J. Clin. Oncol. 34(12), e110–e116 (2016).Crossref, Medline, CAS, Google Scholar

Vol. 13, No. 18

Metrics

Downloaded 270 times

History

Published online 22 August 2017

Published in print August 2017

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download